VIVE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VIVE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Viveve Medical's enterprise value is $-0.02 Mil. Viveve Medical's EBITDA for the trailing twelve months (TTM) ended in Sep. 2022 was $-20.43 Mil. Therefore, Viveve Medical's EV-to-EBITDA for today is 0.00.
The historical rank and industry rank for Viveve Medical's EV-to-EBITDA or its related term are showing as below:
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-11), Viveve Medical's stock price is $0.0003. Viveve Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 was $-2.650. Therefore, Viveve Medical's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
The historical data trend for Viveve Medical's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viveve Medical Annual Data | |||||||||||||||||||||
Trend | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | |||||||||||
EV-to-EBITDA | Get a 7-Day Free Trial | -3.15 | -1.12 | - | -0.50 | 0.09 |
Viveve Medical Quarterly Data | ||||||||||||||||||||
Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | |
EV-to-EBITDA | Get a 7-Day Free Trial | -0.37 | 0.09 | -0.14 | -0.15 | -0.35 |
For the Medical Devices subindustry, Viveve Medical's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Viveve Medical's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Viveve Medical's EV-to-EBITDA falls into.
Viveve Medical's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | -0.023 | / | -20.426 | |
= | 0.00 |
Viveve Medical's current Enterprise Value is $-0.02 Mil.
Viveve Medical's EBITDA for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-20.43 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viveve Medical (OTCPK:VIVE) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Viveve Medical's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 0.0003 | / | -2.650 | |
= | At Loss |
Viveve Medical's share price for today is $0.0003.
Viveve Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.650.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of Viveve Medical's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Presnell Sharon Collins | director | 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121 |
Goldman Sachs Group Inc | 10 percent owner | 200 WEST STREET, NEW YORK NY 10282 |
Goldman Sachs & Co. Llc | 10 percent owner | 200 WEST STREET, NEW YORK NY 10282 |
Wilmot B. Harkey | 10 percent owner | C/O NANTAHALA CAPITAL MANAGEMENT, LLC, 130 MAIN ST. 2ND FLOOR, NEW CANAAN CT 06840 |
Daniel Mack | 10 percent owner | C/O NANTAHALA CAPITAL MANAGEMENT, LLC, 130 MAIN ST. 2ND FLOOR, NEW CANAAN CT 06840 |
Nantahala Capital Management, Llc | 10 percent owner | 130 MAIN ST., 2ND FLOOR, NEW CANAAN CT 06840 |
Karen L. Zaderej | director | AXOGEN INC., 13859 PROGRESS BLVD, SUITE 100, ALACHUA FL 32615 |
Steven L Basta | director | 1875 S GRANT STREET SUITE 110, SAN MATEO CA 94402 |
Scott Durbin | officer: Chief Financial Officer | PO BOX 376, ANN ARBOR MI 48106 |
James G. Atkinson | officer: CBO & President | 150 COMMERCIAL STREET, SUNNYVALE CA 94086 |
Patricia Scheller | director, officer: CEO and Director | 150 COMMERCIAL STREET, SUNNYVALE CA 94086 |
Jon M Plexico | director, 10 percent owner | 16430 N SCOTTSDALE RD 450, SCOTTSDALE AZ 85254 |
Stonepine Capital Management, Llc | director, 10 percent owner | 919 NW BOND STREET, SUITE 204, BEND OR 97703 |
Timothy P Lynch | director, 10 percent owner | 919 NW BOND STREET, SUITE 204, BEND OR 97703 |
Daniel Janney | director, 10 percent owner | PO BOX 7414, JACKSON WY 83002 |
From GuruFocus
By ACCESSWIRE ACCESSWIRE • 07-07-2021
By ACCESSWIRE ACCESSWIRE • 03-03-2022
By ACCESSWIRE ACCESSWIRE • 10-28-2021
By ACCESSWIRE ACCESSWIRE • 07-12-2022
By ACCESSWIRE ACCESSWIRE • 06-03-2021
By ACCESSWIRE ACCESSWIRE • 04-28-2022
By ACCESSWIRE ACCESSWIRE • 09-07-2021
By ACCESSWIRE ACCESSWIRE • 11-02-2021
By ACCESSWIRE ACCESSWIRE • 10-27-2022
By ACCESSWIRE ACCESSWIRE • 08-03-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.